Perrigo Company (PRGO) is a dominant player store brand market over-the-counter (OTC) pharmaceutical market and an industry leader in pharmaceutical technologies. The Dublin, Ireland-based acquired Omega Pharma to form a leading over-the-counter health care company. Post-acquisition, Perrigo changed its fiscal year to the calendar year. The company also changed its reporting segments to Consumer HealthCare, Branded Consumer Healthcare (newly acquired Omega business), Rx Pharmaceuticals, Specialty Sciences and Other (which will include the active pharmaceutical ingredients (API) business).
Meanwhile, Mylan is looking to acquire Perrigo and has received the European regulatory approval to move forward with its proposed buyout. Investor focus is expected to remain on Mylan-Perrigo updates in the near term.
Perrigo has an impressive earnings track record with the company delivering positive earnings surprises in three of the last four quarters with an average surprise of 3.46%.
Currently, Perrigo has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings : Perrigo beat on earnings by a wide margin. Our consensus called for EPS of $1.97, and the company reported EPS of $2.18.
Revenue : Revenues were in line with expectations. Perrigo posted revenues of $1.5 billion which was in line our consensus estimate.
Key Stats : Revenues at Perrigo increased year-over-year benefiting from higher sales in Branded Consumer Healthcare segment and Rx segment. Increase in revenues were partially offset by unfavorable foreign currency movements and lower sales volumes in the VMS and animal health categories. The company reiterated its earnings guidance. The company expects 2015 earnings in the range of $7.50 to $8.00 per share
Check back later for our full write up on this Perrigo earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment